MedDataX Logo

Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

NCT ID: NCT00887224

Last Updated: 2014-11-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

874 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-06-30

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to compare the long-term efficacy and safety of desvenlafaxine succinate sustained release versus placebo in adults with Major Depressive Disorder, using a randomized withdrawal design. Randomized withdrawal means that after receiving desvenlafaxine succinate sustained release for a predetermined period of time, subjects will be selected by chance to either continue receiving the study drug or to be withdrawn from the study drug and receive placebo for the remainder of their participation in the trial. Subjects will not know to which group they have been assigned.

The study consists of an up to 14-day screening period followed by an 8-week open-label period in which subjects will knowingly receive 50 mg/day of desvenlafaxine succinate sustained release. Subjects who do not respond to treatment, demonstrating no significant change in their depressive symptoms, will be withdrawn from participation at the end of this period. Responding subjects will receive an additional 3 months of open-label desvenlafaxine succinate sustained release at the same dose. Subjects with stable response to treatment at the conclusion of this 3 month period will be randomized to either desvenlafaxine succinate sustained release at 50 mg/day or placebo in a blinded manner for an additional 6 months or until symptoms of depression return. Following discontinuation at any point after enrollment in the study, subjects will receive two weeks of follow-up monitoring, including one week of blinded taper with 25 mg/day of desvenlafaxine succinate sustained release treatment for any subjects who have been taking desvenlafaxine succinate sustained release prior to discontinuation. Subjects assigned to placebo will receive a blinded placebo taper. Following taper, subjects will be evaluated for one additional week to monitor safety.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Desvenlafaxine succinate sustained release 50 mg

Group Type EXPERIMENTAL

Desvenlafaxine succinate sustained release 50 mg

Intervention Type DRUG

50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.

Desvenlafaxine succinate sustained release 25 mg

Intervention Type DRUG

25 mg tablet for taper, once daily for 1 week

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Desvenlafaxine succinate sustained release 50 mg

50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.

Intervention Type DRUG

Desvenlafaxine succinate sustained release 25 mg

25 mg tablet for taper, once daily for 1 week

Intervention Type DRUG

Placebo

Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pristiq Pristiq

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult, outpatient with primary diagnosis of Major Depressive Disorder (depressive symptoms for at least 30 days prior to screening)
* Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) total score of \>= 20
* Clinical Global Impressions Scale-Severity (CGI-S) score of \>= 4.

Exclusion Criteria

* Significant risk of suicide as assessed by clinician judgment, HAM-D17 and Columbia Suicide-Severity Rating Scale scores.
* Past treatment with desvenlafaxine succinate sustained release.
* Other eligibility criteria also apply.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Beverly Hills, California, United States

Site Status

Pfizer Investigational Site

Encino, California, United States

Site Status

Pfizer Investigational Site

Los Alamitos, California, United States

Site Status

Pfizer Investigational Site

Orange, California, United States

Site Status

Pfizer Investigational Site

Upland, California, United States

Site Status

Pfizer Investigational Site

Aurora, Colorado, United States

Site Status

Pfizer Investigational Site

Jacksonville, Florida, United States

Site Status

Pfizer Investigational Site

South Miami, Florida, United States

Site Status

Pfizer Investigational Site

St. Petersburg, Florida, United States

Site Status

Pfizer Investigational Site

St. Petersburg, Florida, United States

Site Status

Pfizer Investigational Site

Atlanta, Georgia, United States

Site Status

Pfizer Investigational Site

Smyrna, Georgia, United States

Site Status

Pfizer Investigational Site

Hoffman Estates, Illinois, United States

Site Status

Pfizer Investigational Site

Rockville, Maryland, United States

Site Status

Pfizer Investigational Site

New York, New York, United States

Site Status

Pfizer Investigational Site

New York, New York, United States

Site Status

Pfizer Investigational Site

Rochester, New York, United States

Site Status

Pfizer Investigational Site

Dayton, Ohio, United States

Site Status

Pfizer Investigational Site

Portland, Oregon, United States

Site Status

Pfizer Investigational Site

San Antonio, Texas, United States

Site Status

Pfizer Investigational Site

Seattle, Washington, United States

Site Status

Pfizer Investigational Site

Edmonton, Alberta, Canada

Site Status

Pfizer Investigational Site

Medicine Hat, Alberta, Canada

Site Status

Pfizer Investigational Site

Kelowna, British Columbia, Canada

Site Status

Pfizer Investigational Site

Vancouver, British Columbia, Canada

Site Status

Pfizer Investigational Site

Bathurst, New Brunswick, Canada

Site Status

Pfizer Investigational Site

Burlington, Ontario, Canada

Site Status

Pfizer Investigational Site

Ottawa, Ontario, Canada

Site Status

Pfizer Investigational Site

Toronto, Ontario, Canada

Site Status

Pfizer Investigational Site

Gatineau, Quebec, Canada

Site Status

Pfizer Investigational Site

Pointe-Claire, Quebec, Canada

Site Status

Pfizer Investigational Site

Sherbrooke, Quebec, Canada

Site Status

Pfizer Investigational Site

Santiago, Chile, Chile

Site Status

Pfizer Investigational Site

Santiago, Chile, Chile

Site Status

Pfizer Investigational Site

Santiago, Chile, Chile

Site Status

Pfizer Investigational Site

Medellín, Antioquia, Colombia

Site Status

Pfizer Investigational Site

Barranquilla, Atlántico, Colombia

Site Status

Pfizer Investigational Site

Bogota, Cundinamarca, Colombia

Site Status

Pfizer Investigational Site

Bucamaranga, Santander Department, Colombia

Site Status

Pfizer Investigational Site

Rijeka, , Croatia

Site Status

Pfizer Investigational Site

Zagreb, , Croatia

Site Status

Pfizer Investigational Site

Tallinn, , Estonia

Site Status

Pfizer Investigational Site

Tallinn, , Estonia

Site Status

Pfizer Investigational Site

Tartu, , Estonia

Site Status

Pfizer Investigational Site

Võru, , Estonia

Site Status

Pfizer Investigational Site

Vöru, , Estonia

Site Status

Pfizer Investigational Site

Espoo, , Finland

Site Status

Pfizer Investigational Site

Helsinki, , Finland

Site Status

Pfizer Investigational Site

Joensuu, , Finland

Site Status

Pfizer Investigational Site

Kuopio, , Finland

Site Status

Pfizer Investigational Site

Seinäjoki, , Finland

Site Status

Pfizer Investigational Site

Tampere, , Finland

Site Status

Pfizer Investigational Site

Turku, , Finland

Site Status

Pfizer Investigational Site

Douai, France, France

Site Status

Pfizer Investigational Site

Caen, , France

Site Status

Pfizer Investigational Site

Dole, , France

Site Status

Pfizer Investigational Site

Douai, , France

Site Status

Pfizer Investigational Site

Orvault, , France

Site Status

Pfizer Investigational Site

Rennes, , France

Site Status

Pfizer Investigational Site

Strenči, Latvia, Latvia

Site Status

Pfizer Investigational Site

Liepāja, , Latvia

Site Status

Pfizer Investigational Site

Sigulda, , Latvia

Site Status

Pfizer Investigational Site

Sigulda, , Latvia

Site Status

Pfizer Investigational Site

Strenči, , Latvia

Site Status

Pfizer Investigational Site

Kaunas, , Lithuania

Site Status

Pfizer Investigational Site

Kaunas, , Lithuania

Site Status

Pfizer Investigational Site

Vilius, , Lithuania

Site Status

Pfizer Investigational Site

Vilnius, , Lithuania

Site Status

Pfizer Investigational Site

Vilnius, , Lithuania

Site Status

Pfizer Investigational Site

Vilnius, , Lithuania

Site Status

Pfizer Investigational Site

Skorzewo, Poznan, Poland

Site Status

Pfizer Investigational Site

Szczecin, , Poland

Site Status

Pfizer Investigational Site

Torun, , Poland

Site Status

Pfizer Investigational Site

Tuszyn, , Poland

Site Status

Pfizer Investigational Site

Wroclaw, , Poland

Site Status

Pfizer Investigational Site

Żuromin, , Poland

Site Status

Pfizer Investigational Site

Brasov, Brașov County, Romania

Site Status

Pfizer Investigational Site

Craiova, Dolj, Romania

Site Status

Pfizer Investigational Site

Bucharest, , Romania

Site Status

Pfizer Investigational Site

Bucharest, , Romania

Site Status

Pfizer Investigational Site

Cluj-Napoca, , Romania

Site Status

Pfizer Investigational Site

Bojnice, , Slovakia

Site Status

Pfizer Investigational Site

Bratislava, , Slovakia

Site Status

Pfizer Investigational Site

Liptovský Mikuláš, , Slovakia

Site Status

Pfizer Investigational Site

Michalovce, , Slovakia

Site Status

Pfizer Investigational Site

Rimavská Sobota, , Slovakia

Site Status

Pfizer Investigational Site

Trenčín, , Slovakia

Site Status

Pfizer Investigational Site

Cape Town, Western Cape, South Africa

Site Status

Pfizer Investigational Site

Durban, , South Africa

Site Status

Pfizer Investigational Site

Paarl, , South Africa

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Chile Colombia Croatia Estonia Finland France Latvia Lithuania Poland Romania Slovakia South Africa

References

Explore related publications, articles, or registry entries linked to this study.

Boyer P, Vialet C, Hwang E, Tourian KA. Efficacy of Desvenlafaxine 50 mg/d Versus Placebo in the Long-Term Treatment of Major Depressive Disorder: A Randomized, Double-Blind Trial. Prim Care Companion CNS Disord. 2015 Aug 27;17(4):10.4088/PCC.14m01711. doi: 10.4088/PCC.14m01711. eCollection 2015.

Reference Type DERIVED
PMID: 26693033 (View on PubMed)

McIntyre RS, Fayyad RS, Guico-Pabia CJ, Boucher M. A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d. Prim Care Companion CNS Disord. 2015 Jun 4;17(3):10.4088/PCC.14m01741. doi: 10.4088/PCC.14m01741. eCollection 2015.

Reference Type DERIVED
PMID: 26644956 (View on PubMed)

McIntyre RS, Fayyad RS, Guico-Pabia CJ, Boucher M. An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive Disorder. Prim Care Companion CNS Disord. 2015 Feb 26;17(1):10.4088/PCC.14m01681. doi: 10.4088/PCC.14m01681. eCollection 2015.

Reference Type DERIVED
PMID: 26137355 (View on PubMed)

Thase ME, Fayyad R, Cheng RF, Guico-Pabia CJ, Sporn J, Boucher M, Tourian KA. Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis. Curr Med Res Opin. 2015 Apr;31(4):809-20. doi: 10.1185/03007995.2015.1020365. Epub 2015 Mar 26.

Reference Type DERIVED
PMID: 25758058 (View on PubMed)

Rosenthal JZ, Boyer P, Vialet C, Hwang E, Tourian KA. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trial. J Clin Psychiatry. 2013 Feb;74(2):158-66. doi: 10.4088/JCP.12m07974.

Reference Type DERIVED
PMID: 23473348 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3151A1-3360&StudyName=Relapse%20Prevention%20Study%20Of%20Desvenlafaxine%20Succinate%20Sustained%20Release%20In%20Outpatients%20With%20Major%20Depressive%20Disorder

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B2061004

Identifier Type: -

Identifier Source: secondary_id

3151A1-3360

Identifier Type: -

Identifier Source: org_study_id